P522: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL
Ruihao Huang(Army Medical University), X Zhang(Army Medical University), Han Xiao(Dalian University of Technology), Xiaoqi Wang(Army Medical University), Jia Liu(Frederick National Laboratory for Cancer Research), Cheng Zhang(Naval Medical Research Command), Hongju Yan(Army Medical University), Lei Gao(Zhejiang Chinese Medical University), Maihong Wang(Army Medical University), Yingying Ma(Army Medical University), Gao Li(Army Medical University)
Cited by 5
Related Papers
Recent advances in CAR-T cell engineering
|Journal of Hematology & Oncology|2020|403
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
|Nature Chemical Biology|2020|114
Metformin is a novel suppressor for transforming growth factor (TGF)-β1
|Scientific Reports|2016|96
Strategies to enhance CAR-T persistence
|Biomarker Research|2022|90